{
  "pmcid": "12466003",
  "sha256": "556f92b256567b82a23d9af633bf0c4a175d5b227cde4fbab20a22d80b74887e",
  "timestamp_utc": "2025-11-09T22:28:20.348711+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.799574742268046,
    "reading_ease": 24.892042525773235,
    "word_count": 194
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Bilateral Superficial Cervical Plexus Block in Thyroid and Parathyroid Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A total of 1507 patients were included, with 753 in the BSCPB group."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study evaluates the efficacy of bilateral superficial cervical plexus block (BSCPB) with and without adjuncts in reducing postoperative pain."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of bilateral superficial cervical plexus block (BSCPB) with and without adjuncts in reducing postoperative pain."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative pain reduction, measured by Visual Analog Scale scores at 6–24 hours post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomization and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 1507 patients were included, with 753 in the BSCPB group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "BSCPB significantly reduced postoperative pain compared to control (pooled risk ratio = 0.390, 95% CI: 0.303–0.501, p<0.05)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD420251039306."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding sources were not disclosed."
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}